CRBP Corbus Pharmaceuticals Holdings, Inc.
Financings ·
Corbus can sell up to $127,500,000 of common stock through Jefferies LLC, which earns a fixed 3% commission on each share. At the $9.40 price the filing uses, new buyers would see $2.46 a share of immediate dilution.
We have not published a story on Corbus Pharmaceuticals Holdings yet. When there is news, it will appear here.
Corbus Pharmaceuticals is a clinical stage company focused on oncology and obesity. Its oncology lead, CRB-701, is a next-generation antibody drug conjugate that targets Nectin-4 on cancer cells and releases the cytotoxic payload monomethyl auristatin E. The company licensed CRB-701 from CSPC Megalith Biopharmaceutical Co. Ltd. in February 2023 for the U.S., Canada, the European Union, the United Kingdom and Australia. A Phase 1/2 Western study in the U.S. and Europe is in dose expansion, and a combination arm with Keytruda (pembrolizumab) began dosing in June 2025. CRB-701 has FDA fast track designation for relapsed or refractory metastatic cervical cancer and for recurrent or metastatic head and neck squamous cell carcinoma. CSPC is running a Phase 3 trial in cervical cancer in China. The second pipeline asset, CRB-913, is a highly peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
| Product or program | What it is | Stage |
|---|---|---|
| CRB-701 | Next-generation Nectin-4 targeting antibody drug conjugate with an MMAE payload for solid tumors | Phase 1/2 Western study in dose expansion; Phase 3 in cervical cancer in China by CSPC |
| CRB-913 | Highly peripherally restricted cannabinoid type-1 receptor inverse agonist for obesity |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $70.1 million | $32.2 million |
| Net income (loss) | -$78.5 million | -$40.2 million |
| Cash from operations | -$64.5 million | -$41.8 million |
| Cash and equivalents | $28.5 million | $17.2 million |
| Short-term investments | $134.8 million | $131.9 million |
Corbus Pharmaceuticals Holdings, Inc. trades under the ticker CRBP on NASDAQ.
Corbus Pharmaceuticals Holdings, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:3371; LS:A3D54P; LSE:0SZI; LSX:A3D54P.
The SEC Central Index Key (CIK) for Corbus Pharmaceuticals Holdings, Inc. is 1595097. Its filings are on SEC EDGAR.
19,341,293 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Corbus Pharmaceuticals Holdings, Inc. under United States.
Our directory classifies Corbus Pharmaceuticals Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Corbus Pharmaceuticals Holdings, Inc. is US21833P3010.
aibio.space lists Corbus Pharmaceuticals Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Corbus Pharmaceuticals is a clinical stage company focused on oncology and obesity. Its oncology lead, CRB-701, is a next-generation antibody drug conjugate that targets Nectin-4 on cancer cells and releases the cytotoxic payload monomethyl auristatin E. The company licensed CRB-701 from CSPC Megalith Biopharmaceutical Co. Ltd. in February 2023 for the U.S., Canada, the European Union, the United Kingdom and Australia.
CRB-701: Next-generation Nectin-4 targeting antibody drug conjugate with an MMAE payload for solid tumors Stage: Phase 1/2 Western study in dose expansion; Phase 3 in cervical cancer in China by CSPC.
CRB-913: Highly peripherally restricted cannabinoid type-1 receptor inverse agonist for obesity Stage: not stated.
Corbus Pharmaceuticals Holdings, Inc. reported a net loss of $78.5 million for the fiscal year ended Dec 31, 2025, and used $64.5 million of cash in operations, per its annual report to the SEC.
$70.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$117.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,5.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio